欢迎访问《现代生物医学进展》编辑部！

目的：探讨布地奈德联合福莫特罗治疗慢性阻塞性肺疾病（COPD）合并感染患者的临床疗效。方法：选择2012 年10 月 ~2014 年10 月我院收治的COPD 合并感染患者共84 例，按照随机数字表法将患者随机分为试验组和对照组。两组患者均给予常规综合治疗，在此基础上对照组给予布地奈德，试验组在对照组治疗基础上联合福莫特罗，观察患者治疗前后血气功能、肺功能指标和临床疗效。结果：治疗后试验组PaCO2显著低于对照组（P<0.05），PaO2和SaO2显著高于对照组（P<0.05）。治疗后试验组 FEV1、FVC 和FEV1/ FVC 均显著高于对照组（P<0.05）。实验组治疗后的总有效率为95.24%，显著高于对照组的78.57%（P<0. 05）。结论：采用布地奈德和福莫特罗联合应用治疗COPD 合并感染患者有协同效果，能够有效改善患者的血气指标、肺功能和临床效果，值得推广应用。

英文摘要:

Objective:To explore the clinical efficacy of budesonide combined with formoterol in treatment of chronic obstructive pulmonary disease (COPD) concurrent infection.Methods:Selected 84 patients with COPD concurrent infection who were treated in our hospital fromOctober 2012 to October 2014, they were divided into experimental group and control group according to the randomnumber table method. Applied conventional therapy on both groups, then the control group was added budesonide, while the experimental group was added budesonide combined with formoterol, observed the blood function index, pulmonary function index in the two groups before and after treatment and their clinical efficacy.Results:PaCO2 in experimental group after treatment was significantly lower than control group (P<0.05), but PaO2 and SaO2 in experimental group after treatment were significantly higher than control group (P<0.05). FEV1, FVC and FEV1/FVC in experimental group after treatment were significantly higher than control group (P<0.05). The total effective rate in the experimental group was 95.24%, which is significantly higher than 78.57% in control group (P<0.05).Conclusion:Budesonide combined with formoterol plays a synergistic effect in treatment of COPD concurrent infection, which can effectively improve the blood function index, lung function and clinical efficacy,and should be applied widely.

View Full Text View/Add Comment Download reader